MDMA, MBDB' and I! I the Classichallucinogens
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ion Channels in Drug Discovery
Department of Physiology and Pharmacology Karolinska Institutet, Stockholm, Sweden Thesis for doctoral degree (Ph.D.) 2008 Thesis for doctoral degree (Ph.D.) 2008 Ion Channels in Drug Discovery - focus on biological assays Ion Channels in Drug Discovery - focus on biological assays Kim Dekermendjian Ion Channels in Drug Discovery - focus on biological - focus on in Drug assays Channels Discovery Ion Kim Dekermendjian Kim Dekermendjian Stockholm 2008 Department of Physiology and Pharmacology Karolinska Institutet, Stockholm, Sweden Ion Channels in Drug Discovery - focus on biological assays Kim Dekermendjian Stockholm 2008 Main Supervisor: Bertil B Fredholm, Professor Department of Physiology and Pharmacology Karolinska Institutet. Co-Supervisor: Olof Larsson, PhD Associated Director Department of Molecular Pharmacology, Astrazeneca R&D Södertälje. Opponent: Bjarke Ebert, Adjunct Professor Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark. and Department of Electrophysiology, H. Lundbeck A/S, Copenhagen, Denmark. Examination board: Ole Kiehn, Professor Department of Neurovetenskap, Karolinska Institutet. Bryndis Birnir, PhD Docent Department of Clinical Sciences, Lund University. Bo Rydqvist, Professor Department of Physiology and Pharmacology Karolinska Institutet. All previously published papers were reproduced with permission from the publisher. Front page (a) Side view of the GABA-A model; the trans membrane domain (TMD) (bottom) spans through the lipid membrane (32 Å) and partly on the extracellular side (12 Å), while the ligand binding domain (LBD) (top) is completely extracellular (60 Å). (b) The LBD viewed from the extracellular side (diameter of 80 Å). (c) The TMD viewed from the extracellular side. Arrows and ribbons (which correspond to ȕ-strands and Į- helices, respectively) are coloured according to position in each individual subunit sequence, as well as in the TM4 of each subunit which is not bonded to the rest of the model (with permission from Campagna-Slater and Weaver, 2007 Copyright © 2006 Elsevier Inc.). -
Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. -
Quantification of Drugs of Abuse in Municipal Wastewater Via SPE and Direct Injection Liquid Chromatography Mass Spectrometry
Anal Bioanal Chem (2010) 398:2701–2712 DOI 10.1007/s00216-010-4191-9 ORIGINAL PAPER Quantification of drugs of abuse in municipal wastewater via SPE and direct injection liquid chromatography mass spectrometry Kevin J. Bisceglia & A. Lynn Roberts & Michele M. Schantz & Katrice A. Lippa Received: 2 June 2010 /Revised: 30 August 2010 /Accepted: 2 September 2010 /Published online: 24 September 2010 # US Government 2010 Abstract We present an isotopic-dilution direct injection 50 ng/L. We also present a modified version of this method reversed-phase liquid chromatography–tandem mass spec- that incorporates solid-phase extraction to further enhance trometry method for the simultaneous determination of 23 sensitivity. The method includes a confirmatory LC separa- drugs of abuse, drug metabolites, and human-use markers in tion (selected by evaluating 13 unique chromatographic municipal wastewater. The method places particular emphasis phases) that has been evaluated using National Institute of on cocaine; it includes 11 of its metabolites to facilitate Standards and Technology Standard Reference Material 1511 assessment of routes of administration and to enhance the Multi-Drugs of Abuse in Freeze-Dried Urine. Seven analytes accuracy of estimates of cocaine consumption. Four opioids (ecgonine methyl ester, ecgonine ethyl ester, anhydroecgo- (6-acetylmorphine, morphine, hydrocodone, and oxycodone) nine methyl ester, m-hydroxybenzoylecgonine, p-hydroxy- are also included, along with five phenylamine drugs benzoyl-ecgonine, ecgonine, and anhydroecgonine) were (amphetamine, methamphetamine, 3,4-methylenedioxy- detected for the first time in a wastewater sample. methamphetamine, methylbenzodioxolyl-butanamine, and 3,4-methylenedioxy-N-ethylamphetamine) and two human- Keywords Wastewater . Illicit drugs . Urinary metabolites . use markers (cotinine and creatinine). -
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. -
MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: Lmmunocytochemical Evidence for Neurotoxicity
The Journal of Neuroscience, August 1988, 8(8): 2788-2803 Methylenedioxyamphetamine (MDA) and Methylenedioxymetham- phetamine (MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: lmmunocytochemical Evidence for Neurotoxicity E. O’Hearn,” G. Battaglia, lab E. B. De Souza,’ M. J. Kuhar,’ and M. E. Molliver Departments of Neuroscience, and Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and ‘Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, Baltimore, Maryland 21224 The psychotropic amphetamine derivatives 3,4-methylene- The synthetic amphetamine derivatives 3,4-methylenedioxy- dioxyamphetamine (MDA) and 3,4-methylenedioxymetham- amphetamine (MDA) and 3,4-methylenedioxymethamphet- phetamine (MDMA) have been used for recreational and amine (MDMA) are potent mood-altering drugs that have at- therapeutic purposes in man. In rats, these drugs cause large tained public interest (Seymour, 1986) due to their widespread, reductions in brain levels of serotonin (5HT). This study self-administration by young adults (e.g., Klein, 1985). These employs immunocytochemistry to characterize the neuro- drugs have also been proposed for medical use in psychotherapy toxic effects of these compounds upon monoaminergic neu- because they produce augmentation of mood and enhanced in- rons in the rat brain. Two weeks after systemic administra- sight (Naranjo et al., 1967; Yensen et al., 1976; Di Leo, 198 1; tion of MDA or MDMA (20 mg/kg, s.c., twice daily for 4 d), Greer and Tolbert, 1986; Grinspoon and Bakalar, 1986). How- there is profound loss of serotonergic (5HT) axons through- ever, concern has been raised about the safety of these com- out the forebrain; catecholamine axons are completely pounds based on evidence that they may be toxic to brain seroto- spared. -
Exploring Non-Covalent Interactions Between Drug-Like Molecules and the Protein Acetylcholinesterase
Exploring non-covalent interactions between drug-like molecules and the protein acetylcholinesterase Lotta Berg Doctoral Thesis, 2017 Department of Chemistry Umeå University, Sweden This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7601-644-2 Elektronisk version tillgänglig på http://umu.diva-portal.org/ Printed by: VMC-KBC Umeå Umeå, Sweden, 2017 “Life is a relationship between molecules, not a property of any one molecule” Emile Zuckerkandl and Linus Pauling 1962 i Table of contents Abstract vi Sammanfattning vii Papers covered in the thesis viii List of abbreviations x 1. Introduction 1 1.1. Drug discovery 1 1.2. The importance of non-covalent interactions 1 1.3. Fundamental forces of non-covalent interactions 2 1.4. Classes of non-covalent interactions 3 1.5. Hydrogen bonds 3 1.5.1. Definition of the hydrogen bond 3 1.5.2. Classical and non-classical hydrogen bonds 4 1.5.3. CH∙∙∙Y hydrogen bonds 5 1.6. Interactions between aromatic rings 6 1.7. Thermodynamics of binding 7 1.8. The essential enzyme acetylcholinesterase 8 1.8.1. The relevance of research focused on AChE 8 1.8.2. The structure of AChE 9 1.8.3. AChE in drug discovery 10 2. Scope of the thesis 12 3. Background to techniques and methods 13 3.1. Structure determination by X-ray crystallography 13 3.1.1. The significance of crystal structures of proteins 13 3.1.2. Data collection and structure refinement 13 3.1.3. Electron density maps 14 3.1.4. -
Ring-Substituted Amphetamine Interactions with Neurotransmitter Receptor Binding Sites in Human Cortex
208 NeuroscienceLetters, 95 (1988) 208-212 Elsevier Scientific Publishers Ireland Ltd. NSL O5736 Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex Pamela A. Pierce and Stephen J. Peroutka Deparmentsof Neurologyand Pharmacology, Stanford University Medical Center, StanJbrd,CA 94305 (U.S.A.) (Received 31 May 1988; Revised version received 11 August 1988; Accepted 12 August 1988) Key words.' Ring-substituted amphetamine; (_+)-3,4-Methylenedioxyamphetamine; ( +_)-3,4-Methylene- dioxyethamphetamine; (_+)-3,4-Methylenedioxymethamphetamine; Ecstasy; 4-Bromo-2,5- dimethoxyphenylisopropylamine binding site; Human cortical receptor The binding affinities of 3 ring-substituted amphetamine compounds were determined at 9 neurotrans- mitter binding sites in human cortex. (_+)-3,4-Methylenedioxyamphetamine (MDAk (_+)-3,4-methylene- dioxyethamphetamine (MDE), and (_+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') all display highest affinity (approximately 1 /tM) for the recently identified 'DOB binding site' labeled by ['TBr]R(-)4-bromo-2,5-dimethoxyphenylisopropylamine ([77Br]R(-)DOB). MDA displays moderate affinity (4-5/iM) for the 5-hydroxytryptaminetA (5-HTr^), 5-HT_D,and =,-adrenergic sites in human cor- tex. MDE and MDMA display lower affinity or are inactive at all other sites tested in the present study. These observations are discussed in relation to the novel psychoactive effects of the ring-substituted amphetamines. A series of ring-substituted amphetamine derivatives exist which are structurally related to both amphetamines and hallucinogens. However, drugs such as (+)-3,4- methylenedioxyamphetamine (MDA), (_+)-3,4-methylenedioxyethamphetamine (MDE), and (+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') ap- pear to produce unique psychoactive effects which are distinct from the effects of both amphetamines and hallucinogens [13, 15]. -
Clinical Pharmacology of Antiмcancer Agents
A CLINI CLINICAL PHARMACOLOGY OF NTI- C ANTI-CANCER AGENTS C AL PHARMA AN Cristiana Sessa, Luca Gianni, Marina Garassino, Henk van Halteren www.esmo.org C ER A This is a user-friendly handbook, designed for young GENTS medical oncologists, where they can access the essential C information they need for providing the treatment which could OLOGY OF have the highest chance of being effective and tolerable. By finding out more about pharmacology from this handbook, young medical oncologists will be better able to assess the different options available and become more knowledgeable in the evaluation of new treatments. ESMO ESMO Handbook Series European Society for Medical Oncology CLINICAL PHARMACOLOGY OF Via Luigi Taddei 4, 6962 Viganello-Lugano, Switzerland Handbook Series ANTI-CANCER AGENTS Cristiana Sessa, Luca Gianni, Marina Garassino, Henk van Halteren ESMO Press · ISBN 978-88-906359-1-5 ISBN 978-88-906359-1-5 www.esmo.org 9 788890 635915 ESMO Handbook Series handbook_print_NEW.indd 1 30/08/12 16:32 ESMO HANDBOOK OF CLINICAL PHARMACOLOGY OF ANTI-CANCER AGENTS CM15 ESMO Handbook 2012 V14.indd1 1 2/9/12 17:17:35 ESMO HANDBOOK OF CLINICAL PHARMACOLOGY OF ANTI-CANCER AGENTS Edited by Cristiana Sessa Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy Luca Gianni Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy Marina Garassino Oncology Department, Istituto Nazionale dei Tumori, Milan, Italy Henk van Halteren Department of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands ESMO Press CM15 ESMO Handbook 2012 V14.indd3 3 2/9/12 17:17:35 First published in 2012 by ESMO Press © 2012 European Society for Medical Oncology All rights reserved. -
Differentially Affect Monoamine Transporters and Abuse Liability
Neuropsychopharmacology (2017) 42, 1950–1961 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability Ernesto Solis Jr1, John S Partilla2, Farhana Sakloth3, Iwona Ruchala4, Kathryn L Schwienteck5, 4 4 3 5 *,2 Louis J De Felice , Jose M Eltit , Richard A Glennon , S Stevens Negus and Michael H Baumann 1In Vivo Electrophysiology Unit, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; 2Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, 3 National Institutes of Health, Baltimore, MD, USA; Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA; 4 5 Department of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Clandestine chemists synthesize novel stimulant drugs by exploiting structural templates known to target monoamine transporters for dopamine, norepinephrine, and serotonin (DAT, NET, and SERT, respectively). 4-Methylamphetamine (4-MA) is an emerging drug of – abuse that interacts with transporters, but limited structure activity data are available for its analogs. Here we employed uptake and release assays in rat brain synaptosomes, voltage-clamp current measurements in cells expressing transporters, and calcium flux assays in cells coexpressing transporters and calcium channels to study the effects of increasing N-alkyl chain length of 4-MA on interactions at DAT, NET, and SERT. In addition, we performed intracranial self-stimulation in rats to understand how the chemical modifications affect abuse liability. -
Biological Target and Its Mechanism He Zuan* Department of Pharmacology, School of Medicine,Shenzhen University, Shenzhen 518000, China
OPEN ACCESS Freely available online Journal of Cell Signaling Editorial Biological Target and Its Mechanism He Zuan* Department of Pharmacology, School of Medicine,Shenzhen University, Shenzhen 518000, China EDITORIAL NOTE 1. There is no direct change in the biological target, but the binding of the substance stops other endogenous substances (such Biological target is whatsoever within an alive organism to which as triggering hormones) from binding to the target. Contingent some other entity (like an endogenous drug or ligand) is absorbed on the nature of the target, this effect is mentioned as receptor and binds, subsequent in a modification in its function or antagonism, ion channel blockade or enzyme inhibition. behaviour. For examples of mutual biological targets are nucleic acids and proteins. Definition is context dependent, and can refer 2. A conformational change in the target is induced by the stimulus to the biological target of a pharmacologically active drug multiple, which results in a change in target function. This change in function the receptor target of a hormone like insulin, or some other target can mimic the effect of the endogenous substance in which case of an external stimulus. Biological targets are most commonly the effect is referred to as receptor agonism or be the opposite of proteins such as ion channels, enzymes, and receptors. The term the endogenous substance which in the case of receptors is referred "biological target" is regularly used in research of pharmaceutical to as inverse agonism. to describe the nastive protein in body whose activity is altered Conservation Ecology: These biological targets are conserved by a drug subsequent in a specific effect, which may a desirable across species, making pharmaceutical pollution of the therapeutic effect or an unwanted adverse effect. -
Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks
bioRxiv preprint doi: https://doi.org/10.1101/2020.03.12.988600; this version posted March 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Uncovering new drug properties in target-based drug-drug similarity networks Lucret¸ia Udrescu1, Paul Bogdan2, Aim´eeChi¸s3, Ioan Ovidiu S^ırbu3,6, Alexandru Top^ırceanu4, Renata-Maria V˘arut¸5, Mihai Udrescu4,6* 1 Department of Drug Analysis, "Victor Babe¸s",University of Medicine and Pharmacy Timi¸soara,Timi¸soara,Romania 2 Ming Hsieh Department of Electrical Engineering, University of Southern California, Los Angeles, CA, USA 3 Department of Biochemistry, "Victor Babe¸s"University of Medicine and Pharmacy Timi¸soara,Timi¸soara,Romania 4 Department of Computer and Information Technology, Politehnica University of Timi¸soara,Timi¸soara,Romania 5 Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania 6 Timi¸soaraInstitute of Complex Systems, Timi¸soara,Romania * [email protected] Abstract Despite recent advances in bioinformatics, systems biology, and machine learning, the accurate prediction of drug properties remains an open problem. Indeed, because the biological environment is a complex system, the traditional approach { based on knowledge about the chemical structures { cannot fully explain the nature of interactions between drugs and biological targets. Consequently, in this paper, we propose an unsupervised machine learning approach that uses the information we know about drug-target interactions to infer drug properties.